Molecular Markers and the Promise of Precision Medicine for Interstitial Lung Disease

被引：4
|
作者：
Newton, Chad A. [1 ]
Herzog, Erica L. [2 ]
机构：
[1] Univ Texas Southwestern Med Ctr Dallas, Dept Internal Med, Div Pulm & Crit Care Med, 5323 Harry Hines Blvd, Dallas, TX 75390 USA
[2] Yale Univ, Yale Sch Med, Dept Med, Sect Pulm Crit Care & Sleep Med, 300 Cedar St TAC441S, New Haven, CT 06520 USA
来源：
CLINICS IN CHEST MEDICINE | 2021年 / 42卷 / 02期
关键词：
Interstitial lung disease; Biomarkers; Precision medicine; Omics; IDIOPATHIC PULMONARY-FIBROSIS; SURFACTANT PROTEIN-C; MUC5B PROMOTER POLYMORPHISM; GENE-EXPRESSION; TELOMERE LENGTH; MITOCHONDRIAL DYSFUNCTION; N-ACETYLCYSTEINE; DISTAL AIRWAYS; ASSOCIATION; SUSCEPTIBILITY;
D O I：
10.1016/j.ccm.2021.03.011
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
The clinical heterogeneity of ILD offers numerous opportunities for biomarker-based precision med-icine. Building up existing approaches, unbiased, omics-based methods could transform categori-zation and management of these disorders. Care-ful, practical, and collaborative approaches to biomarker discovery and validation may unveil new molecular endotypes and improve patient outcomes in this complex field.
引用
收藏
页码：357 / 364
页数：8
相关论文
共 50 条
  • [21] CIRCULATING MARKERS OF INTERSTITIAL LUNG DISEASE AND SUBSEQUENT RISK OF LUNG CANCER
    Shiels, M. S.
    Chaturvedi, A.
    Katki, H.
    Gochuico, B.
    Caporaso, N.
    Engels, E.
    AMERICAN JOURNAL OF EPIDEMIOLOGY, 2011, 173 : S88 - S88
  • [22] Treatable traits: a comprehensive precision medicine approach in interstitial lung disease, but why were acute exacerbations not considered?
    Moran-Mendoza, Onofre
    Coppola-Lamas, Maria A.
    Alrubai, Elham
    Paredes, Carla
    EUROPEAN RESPIRATORY JOURNAL, 2023, 62 (03)
  • [23] Interstitial lung disease and lung cancer: Decisions, precision, and tuna fish sandwiches
    Ferraris, Victor A.
    JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2017, 154 (03): : 1097 - 1099
  • [24] Pathologic and Molecular Characteristics of Lung Cancer in Interstitial Lung Disease
    Alshamlan, Najd
    Pal, Prodipto
    Cabanero, Michael
    Tsao, Ming
    Hsu, Ying-Han
    LABORATORY INVESTIGATION, 2023, 103 (03) : S1591 - S1591
  • [25] BASELINE INFLAMMATORY MARKERS AND SURVIVAL IN PATIENTS WITH INTERSTITIAL LUNG DISEASE
    Hatch, M.
    Goh, N.
    Khor, Y.
    RESPIROLOGY, 2019, 24 : 167 - 167
  • [26] Molecular biology tools for precision medicine in managing lung cancer
    Mahesh, P. A.
    LUNG INDIA, 2018, 35 (01) : 1 - 3
  • [27] Recent advances in the molecular genetics and precision medicine of lung carcinoma
    Pirooznia, Mehdi
    Wu, Xiaogang
    Bella, Jonathan N.
    Zhang, Fan
    Jovanovic, Dragana
    FRONTIERS IN GENETICS, 2024, 15
  • [28] Toward precision medicine in glioblastoma: the promise and the challenges
    Prados, Michael D.
    Byron, Sara A.
    Tran, Nhan L.
    Phillips, Joanna J.
    Molinaro, Annette M.
    Ligon, Keith L.
    Wen, Patrick Y.
    Kuhn, John G.
    Mellinghoff, Ingo K.
    de Groot, John F.
    Colman, Howard
    Cloughesy, Timothy F.
    Chang, Susan M.
    Ryken, Timothy C.
    Tembe, Waibhav D.
    Kiefer, Jeffrey A.
    Berens, Michael E.
    Craig, David W.
    Carpten, John D.
    Trent, Jeffrey M.
    NEURO-ONCOLOGY, 2015, 17 (08) : 1051 - 1063
  • [29] Precision medicine and monoclonal antibodies: breach of promise?
    Garattini, Livio
    Padula, Anna
    CROATIAN MEDICAL JOURNAL, 2019, 60 (03) : 284 - 289
  • [30] The promise of precision: datafication in medicine, agriculture and education
    Kuch, Declan
    Kearnes, M.
    Gulson, K.
    POLICY STUDIES, 2020, 41 (05) : 527 - 546
12345